BRPI0817052A2 - Métodos para o tratamento de uma doença auto-imune e distúrbio, método de inibição de atividade biológica, método para aumentar uma atividade biológica, método para a detecção de uma doença auto-imune, população de células t cd4+, método para isolar uma população de células t cd4+, kit, uso de um modulador crtam, modulador crtam e anticorpo. - Google Patents

Métodos para o tratamento de uma doença auto-imune e distúrbio, método de inibição de atividade biológica, método para aumentar uma atividade biológica, método para a detecção de uma doença auto-imune, população de células t cd4+, método para isolar uma população de células t cd4+, kit, uso de um modulador crtam, modulador crtam e anticorpo.

Info

Publication number
BRPI0817052A2
BRPI0817052A2 BRPI0817052A BRPI0817052A2 BR PI0817052 A2 BRPI0817052 A2 BR PI0817052A2 BR PI0817052 A BRPI0817052 A BR PI0817052A BR PI0817052 A2 BRPI0817052 A2 BR PI0817052A2
Authority
BR
Brazil
Prior art keywords
crtam
modulator
biological activity
autoimmune disease
population
Prior art date
Application number
Other languages
English (en)
Inventor
Andrew Chan
Jung-Hua Yeh
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of BRPI0817052A2 publication Critical patent/BRPI0817052A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0081—Purging biological preparations of unwanted cells
    • C12N5/0087—Purging against subsets of blood cells, e.g. purging alloreactive T cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
BRPI0817052 2007-08-30 2008-08-29 Métodos para o tratamento de uma doença auto-imune e distúrbio, método de inibição de atividade biológica, método para aumentar uma atividade biológica, método para a detecção de uma doença auto-imune, população de células t cd4+, método para isolar uma população de células t cd4+, kit, uso de um modulador crtam, modulador crtam e anticorpo. BRPI0817052A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US96905907P 2007-08-30 2007-08-30
US3402108P 2008-03-05 2008-03-05
PCT/US2008/074908 WO2009029883A2 (en) 2007-08-30 2008-08-29 Methods and compositions for modulating t cells

Publications (1)

Publication Number Publication Date
BRPI0817052A2 true BRPI0817052A2 (pt) 2015-03-24

Family

ID=39929595

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0817052 BRPI0817052A2 (pt) 2007-08-30 2008-08-29 Métodos para o tratamento de uma doença auto-imune e distúrbio, método de inibição de atividade biológica, método para aumentar uma atividade biológica, método para a detecção de uma doença auto-imune, população de células t cd4+, método para isolar uma população de células t cd4+, kit, uso de um modulador crtam, modulador crtam e anticorpo.

Country Status (10)

Country Link
US (1) US20100247430A1 (pt)
EP (1) EP2190468A2 (pt)
JP (1) JP2010538018A (pt)
KR (1) KR20100067089A (pt)
CN (1) CN101854949A (pt)
AU (1) AU2008292854A1 (pt)
BR (1) BRPI0817052A2 (pt)
CA (1) CA2715305A1 (pt)
MX (1) MX2010002028A (pt)
WO (1) WO2009029883A2 (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2069793B9 (en) 2006-08-29 2017-08-16 Oxford BioTherapeutics Ltd Identification of protein associated with hepatocellular carcinoma, glioblastoma and lung cancer
JP5816558B2 (ja) 2009-03-05 2015-11-18 メダレックス・リミテッド・ライアビリティ・カンパニーＭｅｄａｒｅｘ， Ｌ．Ｌ．Ｃ． Ｃａｄｍ１に特異的な完全ヒト抗体
KR101317507B1 (ko) * 2010-08-30 2013-10-15 가톨릭대학교 산학협력단 레바미피드를 유효성분으로 포함하는 암 또는 면역질환의 예방 또는 치료용 조성물
CA2840484C (en) * 2011-06-29 2020-04-14 Cellestis Limited A cell mediated immune response assay with enhanced sensitivity
US10260089B2 (en) 2012-10-29 2019-04-16 The Research Foundation Of The State University Of New York Compositions and methods for recognition of RNA using triple helical peptide nucleic acids
AU2015290554A1 (en) * 2014-07-18 2017-03-09 Kyoto University Method for inducing T cells for cell-based immunotherapy from pluripotent stem cells
KR102546296B1 (ko) * 2014-10-31 2023-06-21 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 변형된 t 세포에서 유전자 발현의 변경 및 그의 용도
US20170022286A1 (en) * 2015-03-23 2017-01-26 The Board Of Trustees Of The Leland Stanford Junior University Medical uses of crtam agonists
JP6536944B2 (ja) * 2015-06-05 2019-07-03 株式会社膠原病研究所 自己免疫疾患の発症に関与する細胞を判定する方法及びその利用
TWI752930B (zh) * 2015-12-23 2022-01-21 德商梅迪基因免疫治療公司 抗原特異性ｔｃｒ的新生成
EP3704154A1 (en) * 2017-11-02 2020-09-09 Oxford BioTherapeutics Ltd Antibodies and methods of use
WO2021092593A1 (en) * 2019-11-08 2021-05-14 The University Of North Carolina At Chapel Hill Use of agonists to augment car t function in solid tumors
US20230416364A1 (en) 2020-08-13 2023-12-28 Bristol-Myers Squibb Company Methods of redirecting of il-2 to target cells of interest
WO2023274286A1 (zh) * 2021-06-30 2023-01-05 南京圣和药业股份有限公司 抗crtam抗体及其应用
CN115807070A (zh) * 2021-09-15 2023-03-17 首都医科大学附属北京胸科医院 一种结核分枝杆菌记忆样nk细胞筛查的标志物及其应用
CN114966057B (zh) * 2022-06-13 2025-10-28 上海市肺科医院 一种结核病的免疫标志物及其应用
AU2023308064A1 (en) 2022-07-11 2025-02-27 Genuv Inc. Cytokine fusion protein

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007500132A (ja) * 2003-07-25 2007-01-11 アムジェン インコーポレイテッド Ｌｄｃａｍのアンタゴニストおよびアゴニスト、並びにその使用法

Also Published As

Publication number Publication date
KR20100067089A (ko) 2010-06-18
EP2190468A2 (en) 2010-06-02
WO2009029883A2 (en) 2009-03-05
CN101854949A (zh) 2010-10-06
WO2009029883A3 (en) 2009-11-05
JP2010538018A (ja) 2010-12-09
AU2008292854A1 (en) 2009-03-05
MX2010002028A (es) 2010-03-15
CA2715305A1 (en) 2009-03-05
US20100247430A1 (en) 2010-09-30

Similar Documents

Publication Publication Date Title
EP4546353A3 (en) Systems and methods for analyzing mixed cell populations
EP2250249A4 (en) CELL CULTURE AND CELL TESTING PROCEDURES USING DIGITAL MICROFLUIDICS
CL2007003649A1 (es) Un conjugado de molecula asociado a anticuerpo monoclonal humano anti-cd70; composicion que comprende al conjugado de molecula asociado a anticuerpo; metodo de inhibicion del crecimiento de celulas tumorales que expresan cd70.
EP2141225A4 (en) CELL CULTURAL DEVICE, CELL CULTURE SYSTEM AND CELL CULTURE PROCESS
EP2344632A4 (en) PROCESS FOR LEADING PLURIPOTENCES IN CELLS
CR20120371A (es) Antagonistas de pcsk9
EP1815244A4 (en) CELL CULTURE DEVICE
DK2186269T3 (da) Systemniveauinformation til diskontinuert modtagelse, cellegenvalg og RACH
EP1978089A4 (en) CELL CULTURE PROCESS AND AUTOMATIC CULTURE SYSTEM USING THEREOF
DK2132562T3 (da) Fremgangsmåder til at vurdere celler og cellekulturer
MX2008011838A (es) Propagacion de celulas primarias.
BRPI0717633A2 (pt) Anticorpo, composição farmacêutica, e, métodos para detectar uma célula expressando cxcr7 em uma amostra biológica, para tratar, prevenir ou melhorar uma doença e para identificar um modulador de cxcr7
BRPI0914919A2 (pt) Método para selecionar um primeiro grupo de células de uma população de células e aparelho. Sistema, método e processo para detectar e alterar seletivamente uma subpopulação de células desejada em uma população de células de espécime.
WO2009126250A3 (en) Reprogramming a cell by inducing a pluripotent gene through rna interference
PT3185012T (pt) Método para identificação, seleção e análise de células tumorais
EP1948014A4 (en) SYSTEM AND METHOD FOR PREDICTING A COGNITIVE DEGRADATION
MY159971A (en) Multipotent/pluripotent cells and methods
PL1977225T3 (pl) Elektrochemiczny bioczujnikowy układ analityczny
MX2009013762A (es) Metodos para tratar medios de cultivo de celulas para uso en biorreactor.
CL2011002959A1 (es) Peptoide, metodo para identificar un ligando peptoide que es especificamente reconocido por las celulas autoinmunes; y su uso contre enfermedades autoinmune.
EP2246414A4 (en) CELL CULTURE PROCESS AND SCREENING METHOD
EP2084534A4 (en) METHOD OF IDENTIFYING, ISOLATING AND USING ENDOCRINE PRECURSOR CELLS FROM THE PANCREAS ADULT ADULT PEOPLE
BRPI0917462A2 (pt) sistema automatizado para seleção e intermediação de células biológicas alógenas armazenadas para transplante, terapia e pesquisa
WO2012166630A3 (en) In vitro test system to evaluate xenobiotics as immune-modulators of drug transport and metabolism in human hepatocytes
CL2012002871A1 (es) Metodo para identificar una población de celulas tr1 en reposo que comprende la deteccion de la expresion en la superficie celular de los marcadores cd4, cd25, cd127 y cd62l; poblacion aislada de celulas tr1; metodo para disminuir una poblacion de celulas tr1; kit para identificar o aislar una poblacion de celulas tr1 en reposo y/o activadas; composicion farmaceutica que comprende una poblacion de celulas tr1 en reposo y/o activadas.

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal acc. article 33 of ipl - extension of time limit for request of examination expired